The drug manufacturing company reported operating results for its fiscal second quarter.
These small-cap biopharma stocks offer intriguing potential in 2020 and beyond.
XBiotech announced a massive deal with Johnson & Johnson subsidiary Janssen, which is thrusting the overlooked biopharma onto the radars of investors.
Investors should remember that CRISPR isn't the only gene editing technology out there. Case in point: ARCUS.
Precision BioSciences provided an expanded update from its first clinical asset. Investors weren't impressed.
A triple-combination therapy from the company triggered responses in 100% of patients with difficult-to-treat blood cancers.
The ambitious cellular medicine developer finally has clinical results for investors to ponder. It's still early, but the updates are promising.
These companies are carving their own paths in cellular medicine. One just posted promising clinical results, while the other aims to do so this month.
Forty Seven jumped on promising data for its lead drug candidate.
These industry leaders aren't getting much love from Mr. Market. That just sets the stage for an inevitable rebound, right?
These two companies are piggybacking on the growth of solar energy and distributed energy generation.
Global emissions reduction efforts are likely to be much more successful if one controversial energy source is included -- if only temporarily.
An amended collaboration agreement limited the types of immune cells that will be pursued by the duo, but that could create more value for Editas Medicine in the long run.
An important clinical trial turned in underwhelming results.
Now that the initial excitement has worn off, investors are correctly responding to the news of a public stock offering.
The business reported a handful of positive developments.
The rare-disease specialist is putting together a respectable end-of-year run.
The gene editing pioneer got a boost from a collaborator and a competitor.
The diagnostic company reported third-quarter 2019 operating results.
Counterintuitively, investors are bidding up the share price after the company announced a public stock offering.